(Q37024510)

17 August 2017

1 reference

title

Permanent prostate seed brachytherapy: a current perspective on the evolution of the technique and its application (English)

1 reference

17 August 2017

1 reference

2

Mack Roach

1 reference

17 August 2017

Arjun Sahgal

1

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 December 2007

1 reference

17 August 2017

number of pages

13

1 reference

inferred from page(s)

published in

Nature Reviews Urology

1 reference

17 August 2017

volume

4

1 reference

17 August 2017

issue

12

1 reference

17 August 2017

page(s)

658-670

1 reference

https://scigraph.springernature.com/pub.10.1038/ncpuro0971

17 August 2017

exact match

0 references

cites work

The emerging role of high-dose-rate brachytherapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

Whole-pelvis, "mini-pelvis," or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

Carcinoma of the prostate gland: MR imaging with pelvic phased-array coils versus integrated endorectal--pelvic phased-array coils

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

Recent developments in tissue-type imaging (TTI) for planning and monitoring treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

Permanent prostate implant using high activity seeds and inverse planning with fast simulated annealing algorithm: A 12-year Canadian experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

Treatment of intermediate-risk prostate cancer with brachytherapy without supplemental pelvic radiotherapy: a review of the H. Lee Moffitt Cancer Center experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

103Pd brachytherapy versus radical prostatectomy in patients with clinically localized prostate cancer: a 12-year experience from a single group practice

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

Comparing PSA outcome after radical prostatectomy or magnetic resonance imaging-guided partial prostatic irradiation in select patients with clinically localized adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

Failure-free survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate tumors in 2222 patients: results from a single practice

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

Comparison of biochemical disease-free survival of patients with localized carcinoma of the prostate undergoing radical prostatectomy, transperineal ultrasound-guided radioactive seed implantation, or definitive external beam irradiation

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

Decline in urinary retention incidence in 805 patients after prostate brachytherapy: the effect of learning curve?

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

Intraoperative planning and evaluation of permanent prostate brachytherapy: report of the American Brachytherapy Society

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

Postimplant dosimetry for (125)I prostate implants: definitions and factors affecting outcome

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

The impact of hormone therapy on post-implant dosimetry and outcome following Iodine-125 implant monotherapy for localised prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

Dosimetric comparison of pre-planned and or-planned prostate seed brachytherapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

A comparison of permanent prostate brachytherapy techniques: preplan vs. hybrid interactive planning with postimplant analysis

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

Real-time optimized intraoperative dosimetry for prostate brachytherapy: a pilot study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

Improved conformality and decreased toxicity with intraoperative computer-optimized transperineal ultrasound-guided prostate brachytherapy.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

Toward a dynamic real-time intraoperative permanent prostate brachytherapy methodology.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

Prostate seed implantation using 3D-computer assisted intraoperative planning vs. a standard look-up nomogram: Improved target conformality with reduction in urethral and rectal wall dose

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

Computing intraoperative dosimetry for prostate brachytherapy using TRUS and fluoroscopy.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

Intraoperative dynamic dosimetry for prostate implants

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

Comparison of biochemical failure definitions for permanent prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

Prostate-specific antigen (PSA) bounce and other fluctuations: which biochemical relapse definition is least prone to PSA false calls? An analysis of 2030 men treated for prostate cancer with external beam or brachytherapy with or without adjuvant a

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

Long-term results of retropubic permanent 125iodine implantation of the prostate for clinically localized prostatic cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

I-125 interstitial implantation for prostate cancer. What have we learned 10 years later?

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

The radial distance of extraprostatic extension of prostate carcinoma: implications for prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

Extent of extracapsular extension in localized prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

Combining external beam radiotherapy with prostate brachytherapy: issues and rationale

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

"Supplemental beam" and prostate brachytherapy: a simple answer to a complicated question?

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

Phase III Trial Comparing Whole-Pelvic Versus Prostate-Only Radiotherapy and Neoadjuvant Versus Adjuvant Combined Androgen Suppression: Radiation Therapy Oncology Group 9413

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

Brachytherapy in men aged < or = 54 years with clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

Biochemical outcome for hormone-naïve intermediate-risk prostate cancer managed with permanent interstitial brachytherapy and supplemental external beam radiation.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

Permanent interstitial brachytherapy in younger patients with clinically organ-confined prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

Long-term prostate cancer control using palladium-103 brachytherapy and external beam radiotherapy in patients with a high likelihood of extracapsular cancer extension

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomised phase three trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

Treatment margins predict biochemical outcomes after prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

Intermediate term biochemical-free progression and local control following 125iodine brachytherapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

Androgen-deprivation therapy does not impact cause-specific or overall survival after permanent prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

The value of endorectal MRI in the early diagnosis of prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

The prostate: MR imaging and spectroscopy. Present and future

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

Magnetic resonance spectroscopic imaging-guided brachytherapy for localized prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

Towards integrating functional imaging in the treatment of prostate cancer with radiation: the registration of the MR spectroscopy imaging to ultrasound/CT images and its implementation in treatment planning.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

Inverse planning for HDR prostate brachytherapy used to boost dominant intraprostatic lesions defined by magnetic resonance spectroscopy imaging

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

Treatment planning for prostate implants using magnetic-resonance spectroscopy imaging.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

Time to metabolic atrophy after permanent prostate seed implantation based on magnetic resonance spectroscopic imaging.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

Biochemical disease-free survival rates following definitive low-dose-rate prostate brachytherapy with dose escalation to biologic target volumes identified with SPECT/CT capromab pendetide.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

Ultrasound imaging of apoptosis: high-resolution non-invasive monitoring of programmed cell death in vitro, in situ and in vivo.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

Ultrasonic spectral parameter characterization of apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

Role of ultrasound in the detection of apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

I-125 versus Pd-103 for low-risk prostate cancer: morbidity outcomes from a prospective randomized multicenter trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

I-125 versus Pd-103 for low-risk prostate cancer: long-term morbidity outcomes from a prospective randomized multicenter controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

Isotope selection for patients undergoing prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

Biologically effective dose values for prostate brachytherapy: effects on PSA failure and posttreatment biopsy results.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (radiation therapy oncology group 98-05)

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: Importance of patient selection and implant quality

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

Risk group stratification in patients undergoing permanent (125)I prostate brachytherapy as monotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

Late toxicity and biochemical recurrence after external-beam radiotherapy combined with permanent-source prostate brachytherapy: analysis of Radiation Therapy Oncology Group study 0019

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

10-year disease-free survival rates after simultaneous irradiation for prostate cancer with a focus on calculation methodology

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

Retrospective stratification of a consecutive cohort of prostate cancer patients treated with a combined regimen of external-beam radiotherapy and brachytherapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0971

7 January 2021

Identifiers

DOI

10.1038/NCPURO0971

1 reference

Dimensions Publication ID

17 August 2017

1024097414

0 references

1 reference